Recent Quotes

My Watchlist

Indicators

Currencies

International

Treasuries

Niagen Bioscience, Inc. - Common Stock (NQ:NAGE)

5.385 -0.145 (-2.62%)

Streaming Delayed Price Updated: 10:50 AM EST, Feb 5, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	113,423
Open	5.490
Bid (Size)	5.380 (800)
Ask (Size)	5.390 (400)
Prev. Close	5.530
Today's Range	5.360 - 5.510
52wk Range	5.330 - 14.69
Shares Outstanding	68,196,526
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Functional Wellness Stocks Explode as $179 Billion Beverage Market Ditches Sugar for Science

January 29, 2026

ISSUED ON BEHALF OF DOSEOLOGY SCIENCES INC.

From Equity Insider

Via GlobeNewswire

Niagen Bioscience Expands HSA/FSA Access for Tru Niagen®, the Leading NAD+ Supplement in the U.S.*

January 15, 2026

From Niagen Bioscience, Inc

Via Business Wire

Performance

YTD	-13.8%	-13.8%
1 Month	-16.5%	-16.5%
3 Month	-21.7%	-21.7%
6 Month	-42.7%	-42.7%
1 Year	-30.4%	-30.4%

More News

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point

January 21, 2026

From USA News Group

Via GlobeNewswire

Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (NR) Patent Portfolio from Queen’s University Belfast

December 22, 2025

From Niagen Bioscience, Inc

Via Business Wire

Earnings Scheduled For August 6, 2025 ↗

August 06, 2025

Via Benzinga

Niagen Bioscience Launches Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. Featuring Niagen® (Patented Nicotinamide Riboside)

November 13, 2025

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience Announces $10 Million Share Repurchase Program

November 06, 2025

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVID

November 12, 2025

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience, Inc. Reports Third Quarter 2025 Financial Results and Reaffirms Increased Full Year Outlook

November 04, 2025

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

October 21, 2025

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience Increases Full Year 2025 Net Sales Outlook to 25% to 30% Year-Over-Year Growth

October 06, 2025

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience's Pharmaceutical-Grade Niagen™ IV and Injections Now Available at over 50 iCRYO Clinics and More than 900 Total Clinics Nationwide

October 01, 2025

From Niagen Bioscience, Inc

Via Business Wire

AboutNADⓇ Debuts as the Leading Online Resource for Scientific Advancements in NAD+

September 16, 2025

From Niagen Bioscience, Inc

Via Business Wire

Breaking Down Niagen Bioscience: 4 Analysts Share Their Views ↗

August 11, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

August 07, 2025

Via Benzinga

Niagen NAGE Q2 2025 Earnings Call Transcript ↗

August 06, 2025

Via The Motley Fool

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

August 06, 2025

Via Benzinga

Stay updated with the stocks that are on the move in today's after-hours session. ↗

August 06, 2025

Via Chartmill

Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook

August 06, 2025

From Niagen Bioscience, Inc.

Via Business Wire

Examining the Future: Niagen Bioscience's Earnings Outlook ↗

August 05, 2025

Via Benzinga

Niagen Bioscience to Present at Canaccord Genuity’s 45th Annual Growth Conference

August 04, 2025

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

July 23, 2025

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson’s Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway

July 08, 2025

From Niagen Bioscience, Inc

Via Business Wire

Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York

July 14, 2025

From Niagen Bioscience, Inc

Via Business Wire

Frequently Asked Questions

Is Niagen Bioscience, Inc. - Common Stock publicly traded?

Yes, Niagen Bioscience, Inc. - Common Stock is publicly traded.

What exchange does Niagen Bioscience, Inc. - Common Stock trade on?

Niagen Bioscience, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Niagen Bioscience, Inc. - Common Stock?

The ticker symbol for Niagen Bioscience, Inc. - Common Stock is NAGE on the Nasdaq Stock Market

What is the current price of Niagen Bioscience, Inc. - Common Stock?

The current price of Niagen Bioscience, Inc. - Common Stock is 5.385

When was Niagen Bioscience, Inc. - Common Stock last traded?

The last trade of Niagen Bioscience, Inc. - Common Stock was at 02/05/26 10:50 AM ET

What is the market capitalization of Niagen Bioscience, Inc. - Common Stock?

The market capitalization of Niagen Bioscience, Inc. - Common Stock is 367.24M

How many shares of Niagen Bioscience, Inc. - Common Stock are outstanding?

Niagen Bioscience, Inc. - Common Stock has 367M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.